(Total Views: 627)
Posted On: 09/12/2020 6:02:29 PM
Post# of 154055
Trodelvy shouldn’t have a big market share. Wonder why Gilead spent the money unless they wanted to diversify and hoped for more. Trodelvy is only to be used after two other therapies. Once we market LL batting 3rd behind us won’t ever be in the ball park. Strike 3 and money not well spent by Gilead.
I think the reason for third tried drug status is their safety record and side effects. Some are life threatening at 1% of trialed participants.
I don’t see this drug taking over the market share from Leronlimab.
INDICATION
TRODELVY™ (sacituzumab govitecan-hziy) is indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
I think the reason for third tried drug status is their safety record and side effects. Some are life threatening at 1% of trialed participants.
I don’t see this drug taking over the market share from Leronlimab.
INDICATION
TRODELVY™ (sacituzumab govitecan-hziy) is indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
(1)
(0)
